Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.2 DKK | 0.00% | -5.19% | +6.38% |
Apr. 23 | Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024 | |
Apr. 23 | Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 23.74 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.38% | 1.79B | B+ | ||
+1.84% | 24.07B | B | ||
-6.34% | 16.75B | A | ||
+10.34% | 10.18B | B- | ||
-17.75% | 2.06B | - | ||
+41.47% | 1.73B | D- | ||
+13.26% | 589M | - | ||
0.00% | 400M | - | - | |
+27.40% | 135M | - | ||
+21.80% | 93.49M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMBLA Stock
- Ratings Embla Medical hf.